Drug intelligence / Profile preview

gorivitug

Development stage: Phase 1
Lead developer: Regeneron Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

Gorivitug (REGN15160) is a human monoclonal antibody developed by Regeneron Pharmaceuticals targeting the spike (S) protein of SARS-CoV-2, the virus responsible for COVID-19. Its mechanism of action involves binding to and inhibiting the SARS-CoV-2 spike glycoprotein, thereby preventing viral entry into host cells. Gorivitug is being investigated primarily for the prevention and treatment of COVID-19. The drug has been evaluated in Phase 1 clinical trials to assess its safety, tolerability, pharmacokinetics, and immunogenicity in healthy adult volunteers[1][3][5].

Other names: gorivitug

Targets

RBD (SARS-CoV-2 spike receptor-binding domain)

Beyond the preview

Go deeper on gorivitug.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gorivitug.

Explore the full profile